Anzeige
Meldung des Tages: Deep-Value-Chance: 60 % Insideranteil – warum dieser Gold-Explorer als Geheimtipp gilt

PTC Therapeutics Aktie News

Aktie
WKN:  A1W0MW ISIN:  US69366J2006 US-Symbol:  PTCT Branche:  Biotechnologie Land:  USA
74,78 $
-0,1 $
-0,13%
63,288 € 21:59:59 Uhr
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
-
KGV
8,64
Index-Zuordnung
-

PTC Therapeutics News

23.06.25 - PR Newswire
Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) PR Newswire
22.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
19.06.25 - PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
17.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
12.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
07.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
01.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
26.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
20.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
12.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
06.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
06.05.25 - PR Newswire
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results PR Newswire
05.05.25 - PR Newswire
PTC518 PIVOT-HD Study Achieves Primary Endpoint
PTC518 PIVOT-HD Study Achieves Primary Endpoint PR Newswire
01.05.25 - PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
25.04.25 - PR Newswire
PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) PR Newswire
24.04.25 - PR Newswire
PTC Therapeutics to Participate at Upcoming Investor Conferences
PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire
17.04.25 - PR Newswire
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results PR Newswire
28.03.25 - PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
28.03.25 - PR Newswire
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe PR Newswire
20.03.25 - PR Newswire
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies PR Newswire

Newssuche

Videos

newspaper
20:00 Uhr
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »